Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchQuercetinQuercetin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Computational identification of selected bioactive compounds from Cedrus deodara as inhibitors against SARS-CoV-2 main protease: a pharmacoinformatics study

Shaik et al., Indian Drugs, doi:10.53879/id.61.02.13859
Feb 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Quercetin for COVID-19
24th treatment shown to reduce risk in July 2021, now with p = 0.002 from 12 studies.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 112 treatments. c19early.org
In Silico study showing that quercetin binds strongly to the SARS-CoV-2 main protease (Mpro). Authors found that out of 49 phytoconstituents from Cedrus deodara, quercetin exhibited the lowest binding energy of approximately -7.2 kcal/mol when interacting with Mpro, forming 4 hydrogen bonds and 1 hydrophobic interaction. Molecular dynamics simulations confirmed the stability of the quercetin-Mpro complex over a 50ns simulation period.
73 preclinical studies support the efficacy of quercetin for COVID-19:
In Silico studies predict inhibition of SARS-CoV-2, or minimization of side effects, with quercetin or metabolites via binding to the spikeA,3,9,10,22,24,25,30,38,39,41,42,62-64, MproB,3,7,9,11,13,15,17,18,20,23,24,30,34,36-38,42,43,45,63-65, RNA-dependent RNA polymeraseC,1,3,9,32,64, PLproD,3,37,45, ACE2E,22,23,28,37,41,63, TMPRSS2F,22, nucleocapsidG,3, helicaseH,3,29,34, endoribonucleaseI,39, NSP16/10J,6, cathepsin LK,26, Wnt-3L,22, FZDM,22, LRP6N,22, ezrinO,40, ADRPP,38, NRP1Q,41, EP300R,16, PTGS2S,23, HSP90AA1T,16,23, matrix metalloproteinase 9U,31, IL-6V,21,35, IL-10W,21, VEGFAX,35, and RELAY,35 proteins. In Vitro studies demonstrate inhibition of the MproB,15,46,51,59 protein, and inhibition of spike-ACE2 interactionZ,47. In Vitro studies demonstrate efficacy in Calu-3AA,50, A549AB,21, HEK293-ACE2+AC,58, Huh-7AD,25, Caco-2AE,49, Vero E6AF,19,42,49, mTECAG,52, and RAW264.7AH,52 cells. Animal studies demonstrate efficacy in K18-hACE2 miceAI,55, db/db miceAJ,52,61, BALB/c miceAK,60, and rats66. Quercetin reduced proinflammatory cytokines and protected lung and kidney tissue against LPS-induced damage in mice60, inhibits LPS-induced cytokine storm by modulating key inflammatory and antioxidant pathways in macrophages5, and inhibits SARS-CoV-2 ORF3a ion channel activity, which contributes to viral pathogenicity and cytotoxicity54.
a. The trimeric spike (S) protein is a glycoprotein that mediates viral entry by binding to the host ACE2 receptor, is critical for SARS-CoV-2's ability to infect host cells, and is a target of neutralizing antibodies. Inhibition of the spike protein prevents viral attachment, halting infection at the earliest stage.
b. The main protease or Mpro, also known as 3CLpro or nsp5, is a cysteine protease that cleaves viral polyproteins into functional units needed for replication. Inhibiting Mpro disrupts the SARS-CoV-2 lifecycle within the host cell, preventing the creation of new copies.
c. RNA-dependent RNA polymerase (RdRp), also called nsp12, is the core enzyme of the viral replicase-transcriptase complex that copies the positive-sense viral RNA genome into negative-sense templates for progeny RNA synthesis. Inhibiting RdRp blocks viral genome replication and transcription.
d. The papain-like protease (PLpro) has multiple functions including cleaving viral polyproteins and suppressing the host immune response by deubiquitination and deISGylation of host proteins. Inhibiting PLpro may block viral replication and help restore normal immune responses.
e. The angiotensin converting enzyme 2 (ACE2) protein is a host cell transmembrane protein that serves as the cellular receptor for the SARS-CoV-2 spike protein. ACE2 is expressed on many cell types, including epithelial cells in the lungs, and allows the virus to enter and infect host cells. Inhibition may affect ACE2's physiological function in blood pressure control.
f. Transmembrane protease serine 2 (TMPRSS2) is a host cell protease that primes the spike protein, facilitating cellular entry. TMPRSS2 activity helps enable cleavage of the spike protein required for membrane fusion and virus entry. Inhibition may especially protect respiratory epithelial cells, buy may have physiological effects.
g. The nucleocapsid (N) protein binds and encapsulates the viral genome by coating the viral RNA. N enables formation and release of infectious virions and plays additional roles in viral replication and pathogenesis. N is also an immunodominant antigen used in diagnostic assays.
h. The helicase, or nsp13, protein unwinds the double-stranded viral RNA, a crucial step in replication and transcription. Inhibition may prevent viral genome replication and the creation of new virus components.
i. The endoribonuclease, also known as NendoU or nsp15, cleaves specific sequences in viral RNA which may help the virus evade detection by the host immune system. Inhibition may hinder the virus's ability to mask itself from the immune system, facilitating a stronger immune response.
j. The NSP16/10 complex consists of non-structural proteins 16 and 10, forming a 2'-O-methyltransferase that modifies the viral RNA cap structure. This modification helps the virus evade host immune detection by mimicking host mRNA, making NSP16/10 a promising antiviral target.
k. Cathepsin L is a host lysosomal cysteine protease that can prime the spike protein through an alternative pathway when TMPRSS2 is unavailable. Dual targeting of cathepsin L and TMPRSS2 may maximize disruption of alternative pathways for virus entry.
l. Wingless-related integration site (Wnt) ligand 3 is a host signaling molecule that activates the Wnt signaling pathway, which is important in development, cell growth, and tissue repair. Some studies suggest that SARS-CoV-2 infection may interfere with the Wnt signaling pathway, and that Wnt3a is involved in SARS-CoV-2 entry.
m. The frizzled (FZD) receptor is a host transmembrane receptor that binds Wnt ligands, initiating the Wnt signaling cascade. FZD serves as a co-receptor, along with ACE2, in some proposed mechanisms of SARS-CoV-2 infection. The virus may take advantage of this pathway as an alternative entry route.
n. Low-density lipoprotein receptor-related protein 6 is a cell surface co-receptor essential for Wnt signaling. LRP6 acts in tandem with FZD for signal transduction and has been discussed as a potential co-receptor for SARS-CoV-2 entry.
o. The ezrin protein links the cell membrane to the cytoskeleton (the cell's internal support structure) and plays a role in cell shape, movement, adhesion, and signaling. Drugs that occupy the same spot on ezrin where the viral spike protein would bind may hindering viral attachment, and drug binding could further stabilize ezrin, strengthening its potential natural capacity to impede viral fusion and entry.
p. The Adipocyte Differentiation-Related Protein (ADRP, also known as Perilipin 2 or PLIN2) is a lipid droplet protein regulating the storage and breakdown of fats in cells. SARS-CoV-2 may hijack the lipid handling machinery of host cells and ADRP may play a role in this process. Disrupting ADRP's interaction with the virus may hinder the virus's ability to use lipids for replication and assembly.
q. Neuropilin-1 (NRP1) is a cell surface receptor with roles in blood vessel development, nerve cell guidance, and immune responses. NRP1 may function as a co-receptor for SARS-CoV-2, facilitating viral entry into cells. Blocking NRP1 may disrupt an alternative route of viral entry.
r. EP300 (E1A Binding Protein P300) is a transcriptional coactivator involved in several cellular processes, including growth, differentiation, and apoptosis, through its acetyltransferase activity that modifies histones and non-histone proteins. EP300 facilitates viral entry into cells and upregulates inflammatory cytokine production.
s. Prostaglandin G/H synthase 2 (PTGS2, also known as COX-2) is an enzyme crucial for the production of inflammatory molecules called prostaglandins. PTGS2 plays a role in the inflammatory response that can become severe in COVID-19 and inhibitors (like some NSAIDs) may have benefits in dampening harmful inflammation, but note that prostaglandins have diverse physiological functions.
t. Heat Shock Protein 90 Alpha Family Class A Member 1 (HSP90AA1) is a chaperone protein that helps other proteins fold correctly and maintains their stability. HSP90AA1 plays roles in cell signaling, survival, and immune responses. HSP90AA1 may interact with numerous viral proteins, but note that it has diverse physiological functions.
u. Matrix metalloproteinase 9 (MMP9), also called gelatinase B, is a zinc-dependent enzyme that breaks down collagen and other components of the extracellular matrix. MMP9 levels increase in severe COVID-19. Overactive MMP9 can damage lung tissue and worsen inflammation. Inhibition of MMP9 may prevent excessive tissue damage and help regulate the inflammatory response.
v. The interleukin-6 (IL-6) pro-inflammatory cytokine (signaling molecule) has a complex role in the immune response and may trigger and perpetuate inflammation. Elevated IL-6 levels are associated with severe COVID-19 cases and cytokine storm. Anti-IL-6 therapies may be beneficial in reducing excessive inflammation in severe COVID-19 cases.
w. The interleukin-10 (IL-10) anti-inflammatory cytokine helps regulate and dampen immune responses, preventing excessive inflammation. IL-10 levels can also be elevated in severe COVID-19. IL-10 could either help control harmful inflammation or potentially contribute to immune suppression.
x. Vascular Endothelial Growth Factor A (VEGFA) promotes the growth of new blood vessels (angiogenesis) and has roles in inflammation and immune responses. VEGFA may contribute to blood vessel leakiness and excessive inflammation associated with severe COVID-19.
y. RELA is a transcription factor subunit of NF-kB and is a key regulator of inflammation, driving pro-inflammatory gene expression. SARS-CoV-2 may hijack and modulate NF-kB pathways.
z. The interaction between the SARS-CoV-2 spike protein and the human ACE2 receptor is a primary method of viral entry, inhibiting this interaction can prevent the virus from attaching to and entering host cells, halting infection at an early stage.
aa. Calu-3 is a human lung adenocarcinoma cell line with moderate ACE2 and TMPRSS2 expression and SARS-CoV-2 susceptibility. It provides a model of the human respiratory epithelium, but many not be ideal for modeling early stages of infection due to the moderate expression levels of ACE2 and TMPRSS2.
ab. A549 is a human lung carcinoma cell line with low ACE2 expression and SARS-CoV-2 susceptibility. Viral entry/replication can be studied but the cells may not replicate all aspects of lung infection.
ac. HEK293-ACE2+ is a human embryonic kidney cell line engineered for high ACE2 expression and SARS-CoV-2 susceptibility.
ad. Huh-7 cells were derived from a liver tumor (hepatoma).
ae. Caco-2 cells come from a colorectal adenocarcinoma (cancer). They are valued for their ability to form a polarized cell layer with properties similar to the intestinal lining.
af. Vero E6 is an African green monkey kidney cell line with low/no ACE2 expression and high SARS-CoV-2 susceptibility. The cell line is easy to maintain and supports robust viral replication, however the monkey origin may not accurately represent human responses.
ag. mTEC is a mouse tubular epithelial cell line.
ah. RAW264.7 is a mouse macrophage cell line.
ai. A mouse model expressing the human ACE2 receptor under the control of the K18 promoter.
aj. A mouse model of obesity and severe insulin resistance leading to type 2 diabetes due to a mutation in the leptin receptor gene that impairs satiety signaling.
ak. A mouse model commonly used in infectious disease and cancer research due to higher immune response and susceptibility to infection.
Shaik et al., 28 Feb 2024, peer-reviewed, 3 authors. Contact: aminaammi786@gmail.com.
In Silico studies are an important part of preclinical research, however results may be very different in vivo.
This PaperQuercetinAll
COMPUTATIONAL IDENTIFICATION OF SELECTED BIOACTIVE COMPOUNDS FROM CEDRUS DEODARA AS INHIBITORS AGAINST SARS-COV-2 MAIN PROTEASE: A PHARMACOINFORMATICS STUDY
Aminabee Shaik, Lakshmana Rao Atmakuri
INDIAN DRUGS, doi:10.53879/id.61.02.13859
Amid the ongoing Covid-19 pandemic, the quest for potent antiviral treatments intensifies. This study focuses on the potential of bioactive compounds from the Himalayan cedar Cedrus deodara against the SARS-CoV-2 virus. Specifically targeting the main protease (M Pro ) and spike protein, the study employs docking trials and molecular dynamics simulations. Compounds such as quercetin, dihydrodehydrodiconiferyl alcohol, and cedeodarin exhibit notable binding affinity, surpassing the reference drug favipiravir. Molecular dynamics simulations affirm the stability of these complexes throughout the simulation period. While these findings underscore promising interactions, it is crucial to emphasize the need for further research and experimental validation to fully explore the therapeutic capabilities of C. deodara in combatting Covid-19.
References
Aminabee, Raveesha, Adithya, Mohansai, Shaherbanu et al., In vivo antinociceptive activity and In silico molecular docking of selected phytoconstituents of methanolic extract of Hypericum japonicum, J. Drug Alcohol Res
Available, Idma, None
Chandramohan, Kaphle, Chekuri, Evaluating andrographolide as a potent inhibitor of NS3-4A protease and its drug resistant mutants using in silico approaches, Adv. Virol
Chaudhuri, Symons, Deval, Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond, Antivir. Res
Cheng, Li, Zhou, AdmetSAR: A comprehensive source and free tool for assessment of chemical ADMET properties, J. Chem. Inf. Model
Du, Xu, Structure of Mpro from COVID-19 virus and discovery of its inhibitors
Gangadharappa, Sharath, Revanasiddappa, Structural insights of metallo-beta-lactamase revealed an effective way of inhibition of enzyme by natural inhibitors, J. Biomol. Struct. Dyn
Goel, Singh, Lagunin, PASS-assisted exploration of new therapeutic potential of natural products, Med. Chem. Res
Hui, Azhar, Madani, The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health -The latest 2019 novel coronavirus outbreak in Wuhan, China, Int. J. Infect. Dis
Hussain, Haleem, Khan, Medicinal plants: a repository of antiviral metabolites, Future Virol
Jassim, Naji, Novel antiviral agents: a medicinal plant perspective, J. Appl. Microbiol
Kar, Sharma, Singh, Natural compounds from Clerodendrum spp. as possible therapeutic candidates against SARS-CoV-2: An in silico investigation, J Biomol. Struct. Dyn
Khurana, Ishar, Gajbhiye, PASS assisted prediction and pharmacological evaluation of novel nicotinic analogs for nootropic activity in mice, Eur. J. Pharmacol
Lin, Hsu, Lin, Antiviral natural products and herbal medicines, J. Tradit. Complem. Med
Lu, Zhao, Li, Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet
Martinez, Sasse, Bronstrup, Antiviral drug discovery: broad-spectrum drugs from nature, Nat. Prod. Rep
Mittal, Goel, Bhargava, PASS-assisted exploration of antidepressant activity of 1,3,4-trisubstituted-β-lactam derivatives, Bioorg. Med. Chem. Lett
Morris, Huey, Lindstrom, Autodock4 and AutoDockTools4: Automated docking with selective receptor flexibility, J. Comput. Chem
Moses, Goossens, Plants for human health: greening biotechnology and synthetic biology, J. Exp. Bot
O'boyle, Banck, James, Open Babel: an open chemical toolbox, J Cheminform
Pangastuti, Amin, Amin, Natural bioactive compound from Moringa oleifera against cancer based on in silico screening, J. Teknol
Prasanth, Aminabee, Rao, Guntupalli Ch, Reddy et al., Inhibitory effects of Manosa alliacea in Freund's adjuvant arthritis on inflammatory markers and its confirmation by In silico strategy, Thai J. Pharm. Sci
Prasanth, Aminabee, Rao, Teja, Bhargavi et al., Antihelmintic activity of Mansoa alliacea against Pheretima posthuma: In vitro and In silico approach, Thai J. Pharm. Sci
Rouchka, Chariker, Chung, Phylogenetic and variant analysis of 1,040 SARS-CoV-2 Genomes
Sander, Freyss, Korff, Datawarrior: an open-source program for chemistry aware data visualization and analysis, J. Chem. Inf. Model
Schaal, Plants and people: our shared history and future, Plants People Planet
Seeliger, Groot, Ligand docking and binding site analysis with PyMOL and Autodock/Vina, J. Comput. Aided Mol. Des
Shaik, Atmakuri, Clinical trials status and approaches of COVID-19 vaccines developed globally: The Recent Updates, Pharma Times
Shaik, Atmakuri, Maram, In vivo antioxidant activity of different fractions of Indigofera barberi against paracetamol induced toxicity in rats, Turk. J. Pharm. Sci
Sussman, Lin, Jiang, Protein Data Bank (PDB): database of three-dimensional structural information of biological macromolecules, Acta Crystallogr. D Biol. Crystallogr
To, Hung, Chan, From SARS coronavirus to novel animal and human coronaviruses, J. Thorac. Dis
Van Der Spoel, Lindahl, Hess, GROMACS: fast, flexible, and free, J. Comput. Chem
Yang, Lou, Sun, AdmetSAR 2.0: Web-service for prediction and optimization of chemical ADMET properties, Bioinformatics
Zhou, Hou, Shen, Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, Cell Discov
Zhu, Zhang, Wang, A novel coronavirus from patients with pneumonia in China, New Engl. J. Med
{ 'indexed': {'date-parts': [[2024, 3, 21]], 'date-time': '2024-03-21T01:28:16Z', 'timestamp': 1710984496790}, 'reference-count': 35, 'publisher': "Indian Drug Manufacturers' Association (IDMA)", 'issue': '02', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2024, 2, 28]]}, 'abstract': '<jats:p>Amid the ongoing Covid-19 pandemic, the quest for potent antiviral treatments ' 'intensifies. This study focuses on the potential of bioactive compounds from the Himalayan ' 'cedar Cedrus deodara against the SARS-CoV-2 virus. Specifically targeting the main protease ' '(MPro) and spike protein, the study employs docking trials and molecular dynamics ' 'simulations. Compounds such as quercetin, dihydrodehydrodiconiferyl alcohol, and cedeodarin ' 'exhibit notable binding affinity, surpassing the reference drug favipiravir. Molecular ' 'dynamics simulations affirm the stability of these complexes throughout the simulation ' 'period. While these findings underscore promising interactions, it is crucial to emphasize ' 'the need for further research and experimental validation to fully explore the therapeutic ' 'capabilities of C. deodara in combatting Covid-19.</jats:p>', 'DOI': '10.53879/id.61.02.13859', 'type': 'journal-article', 'created': {'date-parts': [[2024, 3, 18]], 'date-time': '2024-03-18T13:23:54Z', 'timestamp': 1710768234000}, 'page': '78-91', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'COMPUTATIONAL IDENTIFICATION OF SELECTED BIOACTIVE COMPOUNDS FROM CEDRUS DEODARA AS INHIBITORS ' 'AGAINST SARS-COV-2 MAIN PROTEASE: A PHARMACOINFORMATICS STUDY', 'prefix': '10.53879', 'volume': '61', 'author': [ {'given': 'Aminabee', 'family': 'Shaik', 'sequence': 'first', 'affiliation': []}, { 'name': 'Department of Pharmacology, V. V. Institute of Pharmaceutical Sciences, ' 'Gudlavalleru-521 356, Andhra Pradesh, India', 'sequence': 'first', 'affiliation': []}, {'given': 'Lakshmana Rao', 'family': 'Atmakuri', 'sequence': 'additional', 'affiliation': []}], 'member': '31700', 'published-online': {'date-parts': [[2024, 3, 14]]}, 'reference': [ { 'key': 'ref0', 'unstructured': '1. World Health Organization. Coronavirus disease 2019 (COVID19): ' 'Situation report. 2020, 70.'}, { 'key': 'ref1', 'doi-asserted-by': 'publisher', 'unstructured': '2. Shaik A., and Atmakuri L.R.: Clinical trials status and approaches of ' 'COVID-19 vaccines developed globally: The Recent Updates. Pharma Times, ' '2022, 54(3), 7-14.', 'DOI': '10.13005/bpj/2214'}, { 'key': 'ref2', 'doi-asserted-by': 'publisher', 'unstructured': '3. Rouchka E.C., Chariker J.H. and Chung D.: Phylogenetic and variant ' 'analysis of 1,040 SARS-CoV-2 Genomes. 2020', 'DOI': '10.20944/preprints202005.0396.v1'}, { 'key': 'ref3', 'unstructured': '4. Lu R., Zhao X. and Li J.: Genomic characterization and epidemiology ' 'of 2019 novel coronavirus: implications for virus origins and receptor ' 'binding. Lancet, 2020, 395, 565-574.'}, { 'key': 'ref4', 'unstructured': '5. Jin Z., Du X. and Xu Y.: Structure of Mpro from COVID-19 virus and ' 'discovery of its inhibitors. bioRxiv. Preprint. 2020'}, { 'key': 'ref5', 'doi-asserted-by': 'publisher', 'unstructured': '6. Hui D.S., Azhar E.I. and Madani T.A.: The continuing 2019-nCoV ' 'epidemic threat of novel coronaviruses to global health - The latest ' '2019 novel coronavirus outbreak in Wuhan, China. Int. J. Infect. Dis., ' '2020, 91, 264-266.', 'DOI': '10.1016/j.ijid.2020.01.009'}, { 'key': 'ref6', 'doi-asserted-by': 'publisher', 'unstructured': '7. Moses T. and Goossens A.: Plants for human health: greening ' 'biotechnology and synthetic biology. J. Exp. Bot., 2017, 68, 4009-4011.', 'DOI': '10.1093/jxb/erx268'}, { 'key': 'ref7', 'doi-asserted-by': 'publisher', 'unstructured': '8. Schaal B.: Plants and people: our shared history and future. Plants ' 'People Planet, 2019, 1, 14-19.', 'DOI': '10.1002/ppp3.12'}, { 'key': 'ref8', 'doi-asserted-by': 'publisher', 'unstructured': '9. Jassim S.A.A. and Naji M. A.: Novel antiviral agents: a medicinal ' 'plant perspective. J. Appl. Microbiol., 2003, 95, 412-427.', 'DOI': '10.1046/j.1365-2672.2003.02026.x'}, { 'key': 'ref9', 'doi-asserted-by': 'publisher', 'unstructured': '10. Hussain W., Haleem K.S. and Khan I.: Medicinal plants: a repository ' 'of antiviral metabolites. Future Virol., 2017, 12, 299-308.', 'DOI': '10.2217/fvl-2016-0110'}, { 'key': 'ref10', 'doi-asserted-by': 'publisher', 'unstructured': '11. Shaik A., Atmakuri L.R. and Maram C.E.: In vivo antioxidant activity ' 'of different fractions of Indigofera barberi against paracetamol induced ' 'toxicity in rats. Turk. J. Pharm. Sci., 2020, 17(2), 136-140.', 'DOI': '10.4274/tjps.galenos.2018.30306'}, { 'key': 'ref11', 'doi-asserted-by': 'publisher', 'unstructured': '12. Chaudhuri S., Symons J.A. and Deval J.: Innovation and trends in the ' 'development and approval of antiviral medicines: 1987-2017 and beyond. ' 'Antivir. Res., 2018, 155, 76-88.', 'DOI': '10.1016/j.antiviral.2018.05.005'}, { 'key': 'ref12', 'doi-asserted-by': 'publisher', 'unstructured': '13. Sander T., Freyss J. and Von Korff M.: Datawarrior: an open-source ' 'program for chemistry aware data visualization and analysis. J. Chem. ' 'Inf. Model, 2015, 55, 460-473.', 'DOI': '10.1021/ci500588j'}, { 'key': 'ref13', 'doi-asserted-by': 'publisher', 'unstructured': '14. Sussman J.L., Lin D. and Jiang J.: Protein Data Bank (PDB): database ' 'of three-dimensional structural information of biological ' 'macromolecules. Acta Crystallogr. D Biol. Crystallogr., 1998, 54, ' '1078-1084.', 'DOI': '10.1107/S0907444998009378'}, { 'key': 'ref14', 'unstructured': '15. Aminabee S.K., Raveesha P., Adithya V., Mohansai M., Shaherbanu, ' 'Harshitha K., Himaja Kasthuri K., Lakshmi Priya M., Chandini Naga ' 'Mallika G. and Lakshmana Rao A.: In vivo antinociceptive activity and In ' 'silico molecular docking of selected phytoconstituents of methanolic ' 'extract of Hypericum japonicum. J. Drug Alcohol Res., 2022, 11(5), ' '01-08.'}, { 'key': 'ref15', 'doi-asserted-by': 'publisher', 'unstructured': '16. Kar P., Sharma N.R. and Singh B.: Natural compounds from ' 'Clerodendrum spp. as possible therapeutic candidates against SARS-CoV-2: ' 'An in silico investigation. J Biomol. Struct. Dyn., 2020, 1-12.', 'DOI': '10.1080/07391102.2020.1780947'}, { 'key': 'ref16', 'doi-asserted-by': 'publisher', 'unstructured': '17. Morris G.M., Huey R. and Lindstrom W.: Autodock4 and AutoDockTools4: ' 'Automated docking with selective receptor flexibility. J. Comput. Chem., ' '2009, 30, 2785-2791.', 'DOI': '10.1002/jcc.21256'}, { 'key': 'ref17', 'doi-asserted-by': 'publisher', 'unstructured': "18. O'Boyle N.M., Banck M. and James C.A. Open Babel: an open chemical " 'toolbox. J Cheminform., 2011, 3, 33.', 'DOI': '10.1186/1758-2946-3-33'}, { 'key': 'ref18', 'doi-asserted-by': 'publisher', 'unstructured': '19. Pangastuti A., Amin I. F. and Amin A.Z.: Natural bioactive compound ' 'from Moringa oleifera against cancer based on in silico screening. J. ' 'Teknol., 2016, 78, 315-318.', 'DOI': '10.11113/jt.v78.8328'}, { 'key': 'ref19', 'unstructured': '20. Prasanth D.S.N.B.K., Aminabee S.K., Lakshmana Rao A., Guntupalli ' 'Ch., Rajasekhar Reddy A., Umasankar K., Koteswara Rao S.N., Rajeshwari ' "P.: Inhibitory effects of Manosa alliacea in Freund's adjuvant arthritis " 'on inflammatory markers and its confirmation by In silico strategy. Thai ' 'J. Pharm. Sci., 2021, 45(6), 532-544.'}, { 'key': 'ref20', 'doi-asserted-by': 'publisher', 'unstructured': '21. Seeliger D. and De Groot B.L.: Ligand docking and binding site ' 'analysis with PyMOL and Autodock/Vina. J. Comput. Aided Mol. Des., 2010, ' '24, 417-422.', 'DOI': '10.1007/s10822-010-9352-6'}, { 'key': 'ref21', 'doi-asserted-by': 'publisher', 'unstructured': '22. Yang H., Lou C. and Sun L.: AdmetSAR 2.0: Web-service for prediction ' 'and optimization of chemical ADMET properties. Bioinformatics., 2019, ' '35, 1067-1069.', 'DOI': '10.1093/bioinformatics/bty707'}, { 'key': 'ref22', 'doi-asserted-by': 'publisher', 'unstructured': '23. Cheng F., Li W. and Zhou Y.: AdmetSAR: A comprehensive source and ' 'free tool for assessment of chemical ADMET properties. J. Chem. Inf. ' 'Model., 2012, 52, 3099-3105.', 'DOI': '10.1021/ci300367a'}, { 'key': 'ref23', 'doi-asserted-by': 'publisher', 'unstructured': '24. Khurana N., Ishar M.P.S. and Gajbhiye A.: PASS assisted prediction ' 'and pharmacological evaluation of novel nicotinic analogs for nootropic ' 'activity in mice. Eur. J. Pharmacol., 2011, 662, 22-30.', 'DOI': '10.1016/j.ejphar.2011.04.048'}, { 'key': 'ref24', 'doi-asserted-by': 'publisher', 'unstructured': '25. Mittal M., Goel R.K. and Bhargava G.: PASS-assisted exploration of ' 'antidepressant activity of 1,3,4-trisubstituted-β-lactam derivatives. ' 'Bioorg. Med. Chem. Lett., 2008, 18, 5347-5349.', 'DOI': '10.1016/j.bmcl.2008.09.064'}, { 'key': 'ref25', 'doi-asserted-by': 'publisher', 'unstructured': '26. Goel R.K., Singh D. and Lagunin A.: PASS-assisted exploration of new ' 'therapeutic potential of natural products. Med. Chem. Res., 2011, 20, ' '1509-1514.', 'DOI': '10.1007/s00044-010-9398-y'}, { 'key': 'ref26', 'doi-asserted-by': 'publisher', 'unstructured': '27. Van Der Spoel D., Lindahl E. and Hess B.: GROMACS: fast, flexible, ' 'and free. J. Comput. Chem., 2005, 26, 1701-1718.', 'DOI': '10.1002/jcc.20291'}, { 'key': 'ref27', 'doi-asserted-by': 'publisher', 'unstructured': '28. Gangadharappa B.S., Sharath R. and Revanasiddappa P.D.: Structural ' 'insights of metallo-beta-lactamase revealed an effective way of ' 'inhibition of enzyme by natural inhibitors. J. Biomol. Struct. Dyn., ' '2020, 38, 3757-3771.', 'DOI': '10.1080/07391102.2019.1667265'}, { 'key': 'ref28', 'doi-asserted-by': 'publisher', 'unstructured': '29. Chandramohan V., Kaphle A. and Chekuri M.: Evaluating ' 'andrographolide as a potent inhibitor of NS3-4A protease and its drug ' 'resistant mutants using in silico approaches. Adv. Virol., 2015, 15, ' '20-67.', 'DOI': '10.1155/2015/972067'}, { 'key': 'ref29', 'unstructured': '30. Prasanth D.S.N.B.K., Aminabee S.K., Lakshmana Rao A., Teja N., ' 'Bhargavi K., Monika Ch., Pujitha B., Sandhya T., Lalitha A. and Siva ' 'Prasad P.: Antihelmintic activity of Mansoa alliacea against Pheretima ' 'posthuma: In vitro and In silico approach. Thai J. Pharm. Sci., 2020, ' '44(3), 86-196.'}, { 'key': 'ref30', 'unstructured': '31. To K.K., Hung I.F. and Chan J.F.: From SARS coronavirus to novel ' 'animal and human coronaviruses. J. Thorac. Dis., 2013, 5(2), S103-S108.'}, { 'key': 'ref31', 'doi-asserted-by': 'publisher', 'unstructured': '32. Zhu N., Zhang D. and Wang W.: A novel coronavirus from patients with ' 'pneumonia in China, 2019. N. Engl. J. Med., 2020, 82, 727-733.', 'DOI': '10.1056/NEJMoa2001017'}, { 'key': 'ref32', 'doi-asserted-by': 'publisher', 'unstructured': '33. Zhou Y., Hou Y. and Shen J.: Network-based drug repurposing for ' 'novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov., 2020, 6, 14.', 'DOI': '10.1038/s41421-020-0153-3'}, { 'key': 'ref33', 'doi-asserted-by': 'publisher', 'unstructured': '34. Lin L.T., Hsu W.C. and Lin C.C.: Antiviral natural products and ' 'herbal medicines. J. Tradit. Complement. Med., 2014, 4, 24-35.', 'DOI': '10.4103/2225-4110.124335'}, { 'key': 'ref34', 'doi-asserted-by': 'publisher', 'unstructured': '35. Martinez J.P., Sasse F. and Bronstrup M.: Antiviral drug discovery: ' 'broad-spectrum drugs from nature. Nat. Prod. Rep., 2015, 32, 29-48.', 'DOI': '10.1039/C4NP00085D'}], 'container-title': 'INDIAN DRUGS', 'original-title': [], 'link': [ { 'URL': 'https://www.indiandrugsonline.org//download/February_2024_61_2_78-91.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 3, 20]], 'date-time': '2024-03-20T10:59:47Z', 'timestamp': 1710932387000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.indiandrugsonline.org/issuesarticle-details?id=MTU0Nw=='}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 2, 28]]}, 'references-count': 35, 'journal-issue': { 'issue': '02', 'published-online': {'date-parts': [[2024, 3, 14]]}, 'published-print': {'date-parts': [[2024, 2, 28]]}}, 'URL': 'http://dx.doi.org/10.53879/id.61.02.13859', 'relation': {}, 'ISSN': ['0019-462X'], 'subject': ['Drug Discovery', 'Pharmaceutical Science', 'Pharmacology'], 'container-title-short': 'IND. DRU.', 'published': {'date-parts': [[2024, 2, 28]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit